Two years after gaining a $33 million launch round for its regenerative medicine platform tech, the Bay Area biotech Surrozen has gone back to the well to raise $50 million to fuel its drive into the clinic.
The key figure in this startup is Christopher Garcia, a Stanford investigator who’s been drawn into the world of Wnt. While much of his labor has centered on cancer research, he’s also spent time developing Wnt surrogates that can play the same role as natural proteins in forming tissue and spurring repair, but hopefully with better drug-like properties that will make them simpler to manufacture and test in humans.
New investors Horizons Ventures, Hartford HealthCare Endowment, and NS Investment jumped into this round, alongside existing investors like The Column Group.
The company says it’s been putting its funds to good use, building “antibody platforms that can function as Wnt or R-spondin mimetics, respectively, in stimulating cell and organ-specific tissue regeneration.”
“Since its founding in 2016, Surrozen has made significant advances in understanding the cell-specific effects of modulating Wnt signaling with bi-specific molecules” said Craig Parker, CEO of Surrozen. “With that understanding, we have developed two novel antibody-based technologies that have recently been validated in multiple disease models. The proceeds of the Series B financing will allow us to advance optimized drug candidates into development for advanced liver disease and one other disease area. Surrozen will also explore applications of the technology in multiple other disease areas.”
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 45,000+ biopharma pros who read Endpoints News by email every day.Free Subscription